Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Castle Biosciences Inc (NQ: CSTL )

22.98 +0.37 (+1.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 285,864
Open 22.70
Bid (Size) 22.20 (1)
Ask (Size) 24.50 (5)
Prev. Close 22.61
Today's Range 22.70 - 23.33
52wk Range 15.58 - 78.92
Shares Outstanding 25,167,365
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Mosaic Tumbles Around 10%, Here's 71 Biggest Movers From Yesterday
Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown... 
Via Benzinga
Patients with Uveal Melanoma Tested with DecisionDx®-UM Report Gaining Value from Test Results In Study Conducted In Collaboration with the Melanoma Research Foundation’s CURE OM Initiative
From Castle Biosciences, Inc.
Via Business Wire

Performance

YTD
-49.64%
-49.64%
1 Month
+3.19%
+3.19%
3 Month
-49.85%
-49.85%
6 Month
-44.22%
-44.22%
1 Year
-70.07%
-70.07%

More News

Read More
Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Announces Support for OHSU’s War on Melanoma™
From Castle Biosciences, Inc.
Via Business Wire
Collaborative Study with Melanoma Research Foundation Confirms Patients Diagnosed with Melanoma Desire Testing with DecisionDx®-Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Present at the JMP Securities Life Sciences Conference
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences’ DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award
From Castle Biosciences, Inc.
Via Business Wire
Data Demonstrating DecisionDx®-Melanoma’s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett’s Esophagus with Low-Grade Dysplasia
From Castle Biosciences, Inc.
Via Business Wire
Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer
From Castle Biosciences
Via Business Wire
Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC
From Castle Biosciences, Inc.
Via Business Wire
7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years
Via InvestorPlace
Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Reports First Quarter 2022 Results
From Castle Biosciences, Inc.
Via Business Wire
Camille Schrier, Miss America 2020, and Castle Biosciences Partner to Expand Awareness of Genetic Testing in Depression and Anxiety
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Recognizes Skin Cancer Awareness Month through Its Support of Patient-Focused Initiatives
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio of Tests
From Castle Biosciences, Inc.
Via Business Wire
Data from Independent, Pooled Analysis Show Significantly Improved Risk Predictions Over Clinical Variables for TissueCypher® Barrett’s Esophagus Test and Ability to Identify Patients at High Risk of Progressing to Esophageal Cancer
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Completes Acquisition of AltheaDx
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Release First Quarter 2022 Financial Results and Host Conference Call on Monday, May 9
From Castle Biosciences, Inc.
Via Business Wire
Expanded SEER Registries Dataset Shows Improved Survival for DecisionDx®-Melanoma Tested Patients Compared to Untested Patients
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Presents Data on Its Inflammatory Skin Disease Pipeline Test at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference
From Castle Biosciences, Inc.
Via Business Wire
51 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.